Akari Therapeutics annual debt-to-equity ratio
2013
2014
2015
2016
2017
2018
2020
2021
2022
2024
2025
Akari Therapeutics Debt-to-Equity Ratio Growth & History (AKTX)
Akari Therapeutics's debt-to-equity ratio was 0.00 for fiscal 2025.
View full Akari Therapeutics company overviewAkari Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.00 | 0.00 | — |
| 2024 | 2024-12-31 | 0.00 | — | — |
| 2022 | 2022-12-31 | 0.00 | 0.00 | — |
| 2021 | 2021-12-31 | 0.00 | 0.00 | — |
| 2020 | 2020-12-31 | 0.00 | — | — |
| 2018 | 2018-12-31 | 0.00 | 0.00 | — |
| 2017 | 2017-12-31 | 0.00 | 0.00 | — |
| 2016 | 2016-12-31 | 0.00 | 0.00 | — |
| 2015 | 2015-12-31 | 0.00 | 0.00 | — |
| 2014 | 2014-12-31 | 0.00 | 0.00 | — |
| 2013 | 2013-12-31 | 0.00 | — | — |
Akari Therapeutics quarterly debt-to-equity ratio
Q4.13
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q4.16
Q2.17
Q4.17
Q2.18
Q4.18
Q2.20
Q3.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.00 | 0.00 | — |
| Q1 2026 | 2026-03-31 | 0.00 | 0.00 | — |
| Q4 2025 | 2025-12-31 | 0.00 | 0.00 | — |
| Q3 2025 | 2025-09-30 | 0.00 | — | — |
| Q2 2025 | 2025-06-30 | 0.00 | — | — |
| Q1 2025 | 2025-03-31 | 0.00 | — | — |
| Q4 2024 | 2024-12-31 | 0.00 | — | — |
| Q2 2023 | 2023-06-30 | 0.00 | 0.00 | — |
| Q4 2022 | 2022-12-31 | 0.00 | 0.00 | — |
| Q2 2022 | 2022-06-30 | 0.00 | 0.00 | — |
| Q4 2021 | 2021-12-31 | 0.00 | 0.00 | — |
| Q2 2021 | 2021-06-30 | 0.00 | 0.00 | — |
| Q4 2020 | 2020-12-31 | 0.00 | — | — |
| Q3 2020 | 2020-09-30 | 0.00 | — | — |
| Q2 2020 | 2020-06-30 | 0.00 | — | — |
| Q4 2018 | 2018-12-31 | 0.00 | 0.00 | — |
| Q2 2018 | 2018-06-30 | 0.00 | 0.00 | — |
| Q4 2017 | 2017-12-31 | 0.00 | 0.00 | — |
| Q2 2017 | 2017-06-30 | 0.00 | 0.00 | — |
| Q4 2016 | 2016-12-31 | 0.00 | 0.00 | — |
| Q2 2016 | 2016-06-30 | 0.00 | 0.00 | — |
| Q1 2016 | 2016-03-31 | 0.00 | 0.00 | — |
| Q4 2015 | 2015-12-31 | 0.00 | 0.00 | — |
| Q3 2015 | 2015-09-30 | 0.00 | — | — |
| Q2 2015 | 2015-06-30 | 0.00 | — | — |
| Q1 2015 | 2015-03-31 | 0.00 | — | — |
| Q4 2014 | 2014-12-31 | 0.00 | 0.00 | — |
| Q4 2013 | 2013-12-31 | 0.00 | — | — |
Akari Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Akari Therapeutics's debt-to-equity ratio increased from 0.00 to 0.00, a change of 0.00. The latest reported quarter, Q2 2026, shows 0.00.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Akari Therapeutics source filings ↗